Overview
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.
Eligibility
Inclusion Criteria:
- Female, Aged ≥18 and ≤70 years
- Histologically confirmed triple negative breast cancer (ER\<10%, PR\<10%, and HER2 negative)
- Subjects with at least one evaluable lesion
- ECOG 0-1
- Adequate organ function
Exclusion Criteria:
- Metastatic disease (Stage IV)
- Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
